Figure 1.
Effect of NaHS and capsazepine on protein and mRNA levels of SP in septic mice.
Mice were randomly given NaHS (10 mg/kg, i.p.) or vehicle (DMSO) at the same time of CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, (A) lung and (B) plasma SP levels, and (C) lung PPT-A mRNA levels were measured. Results shown are the mean values ± SEM (n = 8–12 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; ‡P<0.05 versus CLP+vehicle; †P<0.01 versus CLP+NaHS+vehicle.
Figure 2.
Effect of NaHS and capsazepine on protein levels of cytokines and chemokines in the lungs and liver of septic mice.
Mice were randomly given NaHS (10 mg/kg, i.p.) or vehicle (DMSO) at the same time of CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, protein levels of (A) TNF-α, (B) IL-1β, (C) IL-6, (D) MIP-1α and (E) MIP-2 were measured. Results shown are the mean values ± SEM (n = 8–12 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; ‡P<0.05 versus CLP+vehicle; †P<0.01 versus CLP+NaHS+vehicle.
Figure 3.
Effect of NaHS and capsazepine on protein levels of adhesion molecules in the lungs and liver of septic mice.
Mice were randomly given NaHS (10 mg/kg, i.p.) or vehicle (DMSO) at the same time of CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, protein levels of (A) P-selectin, (B) E-selectin, (C) ICAM-1, and (D) VCAM-1 were measured. Results shown are the mean values ± SEM (n = 8–12 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; ‡P<0.05 versus CLP+vehicle; †P<0.01 versus CLP+NaHS+vehicle.
Figure 4.
Effect of NaHS and capsazepine on liver dysfunction and lung edema in septic mice.
Mice were randomly given NaHS (10 mg/kg, i.p.) or vehicle (DMSO) at the same time of CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, plasma levels of (A) ALT and (B) AST, and (C) lung wet-to-dry weight ratio were measured. Results shown are the mean values ± SEM (n = 10–15 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; ‡P<0.05 versus CLP+vehicle; †P<0.01 versus CLP+NaHS+vehicle.
Figure 5.
Effect of PAG and capsazepine on protein and mRNA levels of SP in septic mice.
Mice were randomly given PAG (50 mg/kg, i.p.) 1 hour before (“prophylactic”) or 1 hour after (“therapeutic”) CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, (A) lung and (B) plasma SP levels, and (C) lung PPT-A mRNA levels were measured. Results shown are the mean values ± SEM (n = 8–12 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle.
Figure 6.
Effect of PAG and capsazepine on protein levels of cytokines and chemokines in the lungs and liver of septic mice.
Mice were randomly given PAG (50 mg/kg, i.p.) 1 hour before (“prophylactic”; PAG+CLP+Vehicle or PAG+CLP+Capz) or 1 hour after (“therapeutic”; CLP+PAG+Vehicle or CLP+PAG+Capz) CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, protein levels of (A) TNF-α, (B) IL-1β, (C) IL-6, (D) MIP-1α and (E) MIP-2 were measured. Results shown are the mean values ± SEM (n = 8–12 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; †P<0.05 versus CLP+vehicle.
Figure 7.
Effect of PAG and capsazepine on protein levels of adhesion molecules in the lungs and liver of septic mice.
Mice were randomly given PAG (50 mg/kg, i.p.) 1 hour before (“prophylactic”; PAG+CLP+Vehicle or PAG+CLP+Capz) or 1 hour after (“therapeutic”; CLP+PAG+Vehicle or CLP+PAG+Capz) CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, protein levels of (A) P-selectin, (B) E-selectin, (C) ICAM-1, and (D) VCAM-1 were measured. Results shown are the mean values ± SEM (n = 8–12 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle.
Figure 8.
Effect of PAG and capsazepine on liver dysfunction and lung edema in septic mice.
Mice were randomly given PAG (50 mg/kg, i.p.) 1 hour before (“prophylactic”) or 1 hour after (“therapeutic”) CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, plasma levels of (A) ALT and (B) AST, and (C) lung wet-to-dry weight ratio were measured. Results shown are the mean values ± SEM (n = 10–15 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; ‡P<0.05 versus CLP+vehicle.
Figure 9.
Effect of NaHS or PAG and capsazepine on ERK1/2 activation in the lungs and liver of septic mice.
Mice were randomly given NaHS (10 mg/kg, i.p.) at the same time of CLP or PAG (50 mg/kg, i.p.) 1 hour before (“prophylactic”) or 1 hour after (“therapeutic”) CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, effect of (A) NaHS or (B) PAG and capsazepine on phospho-ERK1/2 and total ERK1/2 expression levels were measured. A representative western blot image is shown, with densitometry data expressed as average ratios of phospho-ERK1/2 to total ERK1/2. Results shown are the mean values ± SEM (n = 6 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; †P<0.01 versus CLP+NaHS+vehicle.
Figure 10.
Effect of NaHS or PAG and capsazepine on IκBα phosphorylation and degradation levels in the lungs and liver of septic mice.
Mice were randomly given NaHS (10 mg/kg, i.p.) at the same time of CLP or PAG (50 mg/kg, i.p.) 1 hour before (“prophylactic”) or 1 hour after (“therapeutic”) CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, effect of NaHS or PAG and capsazepine on (A and B) phospho-IκBα and (C and D) IκBα expression levels were measured. A representative western blot image is shown, with densitometry data expressed as average ratios of phospho-IκBα to HPRT and IκBα to HPRT levels. Results shown are the mean values ± SEM (n = 6 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; ‡P<0.05 versus CLP+vehicle; †P<0.01 versus CLP+NaHS+vehicle.
Figure 11.
Effect of NaHS or PAG and capsazepine and effect of NaHS and PD98059 on NF-κB activation in nuclear extracts of lung and liver tissues in septic mice.
Mice were randomly given NaHS (10 mg/kg, i.p.) at the same time of CLP or PAG (50 mg/kg, i.p.) 1 hour before (“prophylactic”) or 1 hour after (“therapeutic”) CLP; and capsazepine (Capz) (15 mg/kg, s.c.) or vehicle (DMSO) 30 minutes before CLP. Some mice were injected PD98059 (10 mg/kg, i.p.) or vehicle (DMSO) 1 hour before CLP. Sham mice were used as controls. Eight hours after CLP or sham operation, effect of (A) NaHS or (B) PAG and capsazepine and (C) effect of NaHS and PD98059 on the DNA-binding activity of NF-κB were measured. Results shown are the mean values ± SEM (n = 8–12 mice per group). *P<0.01 versus sham; **P<0.01 versus CLP+vehicle; †P<0.01 versus CLP+NaHS+vehicle. ‡P<0.01 versus CLP+NaHS+vehicle.
Figure 12.
Schematic summary of signaling events in H2S-induced neurogenic inflammation in a murine model of polymicrobial sepsis.
H2S has been demonstrated to be overproduced in sepsis. H2S stimulation of TRPV1 and the downstream release of SP lead to the activation of ERK1/2, which subsequently induces the phosphorylation and degradation of IκBα, as well as the translocation and activation of NF-κB, thereby leading to SIRS and MODS characteristic of severe sepsis. indicates exogenous administration;
indicates inhibition.